SGEN - Merck succeeds in Phase 3 trial for bladder cancer therapy
2023-09-22 06:49:12 ET
More on Merck
- Seeking Alpha’s Quant Rating on Merck
- Historical earnings data for Merck
- Financial information for Merck
- Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects
- Merck: A Blue-Chip Dividend Stock Worth Buying
For further details see:
Merck succeeds in Phase 3 trial for bladder cancer therapy